Gaining market access for new drug therapies is a fast-moving target.

Overcoming hurdles to market access is no small matter. Increasingly, cost-effectiveness and cost-containment are trumping safety and efficacy. 

Forward-thinking biopharma is looking for new ways to anticipate the criteria (we call it “context”), against which their next drug will be evaluated by agencies / payers for reimbursement. 

Let Context Matters put you in control of your blueprint for market access with the right data and technology.




Insights and Research

Upcoming Events

ISPOR 21st
annual meeting

May 21-25
Washington, DC